Retatrutide vs. Tirzepatide: Triple Agonist vs. Dual Agonist. What the Research Shows
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated March 2026
Important: We are not doctors. Everything in this article is based on published research and publicly available clinical trial data. It is not medical advice. Talk to your physician before changing any medication or health protocol.
Key Takeaways
- Tirzepatide targets two receptors (GIP and GLP-1). Retatrutide targets three (GIP, GLP-1, and glucagon). That third receptor is what sets them apart.
- Phase 3 data for retatrutide (TRIUMPH-4) showed 28.7% body weight loss at 68 weeks. Tirzepatide's SURMOUNT-1 Phase 3 trial showed 22.5% at 72 weeks (PMID 35658024).
- Both drugs come from Eli Lilly. Tirzepatide is FDA approved (Mounjaro/Zepbound, including a new 2024 sleep apnea indication). Retatrutide is not FDA approved. Primary obesity trial results (TRIUMPH-1 and TRIUMPH-2) are expected in 2026.
- A new safety signal emerged in TRIUMPH-4: dysesthesia (abnormal skin sensations) occurred in 8.8% of patients at 9 mg and 20.9% at 12 mg. This signal was not observed in Phase 2.
- A head-to-head trial comparing both drugs directly is now underway (NCT06662383). Results expected 2026-2027.
- Glucagon receptor activation adds direct fat oxidation and increased energy expenditure on top of appetite suppression. That is the key pharmacological difference.
Quick Reference: Retatrutide vs. Tirzepatide
| Factor | Retatrutide | Tirzepatide |
|---|---|---|
| Receptor targets | GIP + GLP-1 + Glucagon | GIP + GLP-1 |
| Manufacturer | Eli Lilly | Eli Lilly |
| Development stage | Phase 3 (TRIUMPH program) | FDA approved |
| Brand name | None (investigational) | Mounjaro / Zepbound |
| Best Phase 3 weight loss | 28.7% at 68 wks (TRIUMPH-4) | 22.5% at 72 wks (SURMOUNT-1) |
| Liver fat reduction | ~82-86% at 24 wks (Phase 2) | Limited published data |
| Dosing frequency | Weekly injection | Weekly injection |
| Monthly cost | Not available (no approval) | ~$299-$1,060/mo (see below) |
| FDA approval | Not approved | Approved (2022/2023/2024) |
| Head-to-head trial | Now enrolling (NCT06662383) | Now enrolling (NCT06662383) |
| Availability | Clinical trials only | Standard prescription |
Both Drugs, Same Lab. Different Architecture
Tirzepatide and retatrutide both come from Eli Lilly's research pipeline. They share significant structural similarities. But the mechanism diverges in one important way. For a complete overview of retatrutide, see our retatrutide guide.
Tirzepatide is a dual agonist that activates the GIP receptor and the GLP-1 receptor simultaneously. That combination proved more effective for weight loss than GLP-1 alone, and it earned FDA approval for type 2 diabetes (Mounjaro) and obesity (Zepbound). Zepbound became the most prescribed weight management medication in 2025.
Retatrutide goes one step further. It is a triple agonist, adding glucagon receptor activation to the same GIP+GLP-1 base. In Phase 2 and the first Phase 3 trial, that additional target appears to drive meaningful additional metabolic effects.
The question researchers are now answering: does the glucagon component add enough benefit, with acceptable safety, to justify the added complexity?
The Mechanism: What Each Receptor Does
To understand why the comparison matters, it helps to understand what each receptor pathway actually does.
GLP-1 Receptor
GLP-1 (glucagon-like peptide-1) receptor activation is the foundation of both drugs. It reduces appetite, slows gastric emptying, stimulates insulin release in response to meals, and suppresses glucagon from the pancreas. This is the core mechanism behind weight loss in this entire drug class.
GIP Receptor
GIP (glucose-dependent insulinotropic polypeptide) receptor activation amplifies the insulin response and may enhance GLP-1 receptor signaling. Tirzepatide's weight loss advantage over semaglutide appears to come largely from this combined GIP+GLP-1 effect.
Glucagon Receptor
This is where retatrutide diverges from tirzepatide. Glucagon receptor activation works through different pathways:
- Direct fat oxidation in adipose tissue and the liver
- Increased hepatic lipid metabolism: glucagon directly signals the liver to break down fat stores
- Higher resting energy expenditure: metabolic rate increases independent of appetite suppression
- Accelerated lipolysis: fat cells release stored fatty acids more readily
In plain terms: GLP-1 and GIP work primarily by reducing how much you eat. Glucagon receptor activation also increases how much fat your body burns. That combination is why retatrutide is generating significant research interest.
One useful analogy: tirzepatide turns down the faucet. Retatrutide turns down the faucet and opens the drain.
Efficacy: What the Trial Data Shows
Retatrutide: Phase 2 Results
The primary Phase 2 trial (PMID 37366315) enrolled adults with obesity (BMI 30-50) without type 2 diabetes. Key findings at 48 weeks:
- At the 12 mg dose, participants lost an average of 24.2% of body weight
- At the 4 mg dose, participants lost approximately 8.96 kg (PMID 36354040)
- Dose-dependent weight loss was observed across all groups
- Fat mass reductions of -15.2%, -26.1%, and -23.2% across dose groups (PMID 40609566)
- Liver fat reduction of approximately 82-86% at the highest dose (PMID 38858523)
Retatrutide: TRIUMPH-4 Phase 3 Results (December 2025)
This is the headline update. In December 2025, Eli Lilly announced the first positive Phase 3 data for retatrutide from TRIUMPH-4.
TRIUMPH-4 enrolled 445 adults with obesity and knee osteoarthritis. Key findings at 68 weeks:
- At 12 mg, participants lost an average of 28.7% of body weight (approximately 71.2 lbs)
- At 9 mg, weight loss results were also statistically significant
- Knee pain scores (WOMAC) reduced by an average of 75.8% at the highest dose
- More than 1 in 8 participants on retatrutide reported being completely pain-free at trial end
- Retatrutide also reduced cardiovascular risk markers including non-HDL cholesterol and systolic blood pressure
Important context: TRIUMPH-4 was conducted in a population with knee osteoarthritis, not a general obesity population. The primary obesity trials (TRIUMPH-1 and TRIUMPH-2) results are still pending in 2026. The 28.7% figure is striking, but the core obesity efficacy data will come from TRIUMPH-1 and TRIUMPH-2.
Tirzepatide: Phase 3 Results (SURMOUNT-1)
Tirzepatide's SURMOUNT-1 trial (PMID 35658024) was a large, rigorous Phase 3 study. Key findings at 72 weeks:
- At 15 mg, participants lost an average of 22.5% of body weight
- At 10 mg, average loss was 21.4%
- At 5 mg, average loss was 16.0%
- Approximately 57% of participants on the highest dose achieved at least 20% body weight loss
SURMOUNT-1 enrolled over 2,500 participants and produced high-confidence results. Tirzepatide has now been prescribed to millions of people since its approval.
Trial Data Comparison Table
| Metric | Tirzepatide 15 mg (SURMOUNT-1) | Retatrutide 12 mg (Phase 2) | Retatrutide 12 mg (TRIUMPH-4, Phase 3) |
|---|---|---|---|
| Average weight loss | 22.5% | 24.2% | 28.7% |
| Trial duration | 72 weeks | 48 weeks | 68 weeks |
| Patients losing 20%+ | ~57% | ~75% | Not yet reported |
| Trial size | 2,539 | 338 | 445 |
| FDA status | Approved | Phase 2 | Phase 3 (OA population) |
| Trial phase | Phase 3 (definitive) | Phase 2 | Phase 3 |
Sources: SURMOUNT-1 (PMID: 35658024), Retatrutide Phase 2 (PMID: 37366315), Eli Lilly TRIUMPH-4 press release
The Weight Loss Numbers in Context
At first glance, retatrutide's 28.7% looks substantially better than tirzepatide's 22.5%. But the comparison still requires caution.
TRIUMPH-4 studied a specific population: adults with obesity AND knee osteoarthritis. The primary obesity trials (TRIUMPH-1 and TRIUMPH-2) will be the definitive comparison. Those results are expected in 2026.
A 2025 network meta-analysis comparing the two compounds (PMC12544991) found retatrutide produced greater absolute weight reduction: -16.34 kg vs tirzepatide's -11.82 kg, and percentage weight loss of -23.77% vs -16.79%.
The weight loss gap is large enough that most researchers expect retatrutide to outperform tirzepatide even after full Phase 3 data from TRIUMPH-1 and TRIUMPH-2 arrives. The triple mechanism provides a biological explanation for the difference.
But there is now also a head-to-head trial directly comparing both compounds in the same population.
Head-to-Head Trial: The Comparison Everyone Has Been Waiting For
One of the biggest updates since this article was first published: Eli Lilly has initiated a direct head-to-head trial comparing retatrutide and tirzepatide (NCT06662383).
The trial enrolls approximately 800 adults with obesity. It will run approximately 89 weeks. This is TRIUMPH-5, and it is designed specifically to answer the question of whether retatrutide outperforms tirzepatide when both are tested in the same controlled trial with the same population.
This is notable because pharmaceutical companies rarely run head-to-head trials against their own products. It signals Lilly has enough confidence in retatrutide's efficacy advantage to test it directly.
Results from TRIUMPH-5 are expected in 2026-2027. When that data arrives, it will be the most important comparison data in this entire field.
Safety and Side Effects
Both drugs share the common side effect profile of GLP-1 receptor agonists: nausea, vomiting, diarrhea, and constipation. These are typically dose-dependent and most pronounced during dose escalation.
Side Effect Comparison Table
| Side Effect | Tirzepatide 15 mg (SURMOUNT-1) | Retatrutide 9 mg (TRIUMPH-4) | Retatrutide 12 mg (TRIUMPH-4) |
|---|---|---|---|
| Nausea | 31% | ~43% | ~43% |
| Vomiting | 13% | ~21% | ~21% |
| Diarrhea | 23% | ~33% | ~33% |
| Constipation | 12% | ~16% | ~16% |
| Dysesthesia | 0% | 8.8% | 20.9% |
| Discontinuation due to AEs | Low | 12.2% | 18.2% |
Sources: SURMOUNT-1, TRIUMPH-4 (Eli Lilly press release, December 2025)
The Dysesthesia Signal: What It Means
Dysesthesia (abnormal skin sensations, often described as tingling or burning) is a unique side effect not seen with tirzepatide.
Here is the updated picture from TRIUMPH-4:
- 8.8% of participants at 9 mg experienced dysesthesia
- 20.9% of participants at 12 mg experienced dysesthesia
- Events were generally mild and rarely led to treatment discontinuation
This signal appeared more prominently in Phase 3 than in Phase 2. That warrants attention. Dysesthesia is attributed to glucagon receptor activation in peripheral nervous tissue. It was not observed in tirzepatide trials because tirzepatide does not activate the glucagon receptor.
The 20.9% rate at the 12 mg dose is not trivial. For context, that is roughly 1 in 5 patients at the highest dose. Most events were mild and manageable, but this is a real differentiator in the tolerability comparison.
Discontinuation Rates
TRIUMPH-4 reported discontinuation rates of 12.2% (9 mg arm) and 18.2% (12 mg arm), compared to 4% in the placebo group. Tirzepatide discontinuation rates from SURMOUNT-1 were lower.
This is meaningful. Higher discontinuation means some patients will not be able to tolerate retatrutide at therapeutic doses. Phase 3 results from TRIUMPH-1 and TRIUMPH-2 (the primary obesity trials) will clarify whether these rates hold in a broader population.
Preclinical Safety Note
Mouse studies (PMID 40094000) have identified cancer-related signals in glucagon receptor pathway research. These are preclinical findings in animal models only. They do not establish cancer risk in humans. But they remain part of the ongoing safety evaluation for retatrutide's Phase 3 program.
Tirzepatide's safety profile is better characterized given its large Phase 3 dataset and years of post-approval real-world use. That is a meaningful practical advantage today.
Liver Effects: A Key Differentiator
Retatrutide's data on liver fat is one of its most striking findings, and it may define how both drugs are ultimately positioned in clinical practice.
In the Phase 2 trial, participants on the 12 mg dose showed an approximately 82-86% reduction in liver fat content at 24 weeks (PMID 38858523). This is substantially larger than what GLP-1 agents alone achieve.
The glucagon receptor component is likely responsible. Glucagon directly activates hepatic fat metabolism pathways. This makes retatrutide potentially important for people with metabolic-associated steatotic liver disease (MASLD, formerly NAFLD) or metabolic dysfunction-associated steatohepatitis (MASH) in addition to obesity.
A dedicated TRIUMPH trial for MASH is underway. If the liver fat results from Phase 2 hold in Phase 3, that indication could move through the approval process faster than the primary obesity indication. Watch TRIUMPH-3 data closely.
Tirzepatide also shows liver fat reduction as a secondary benefit of weight loss, but published data on direct liver fat endpoints is less prominent in its current trial record.
Availability: The Deciding Factor for Most People Right Now
This is where the comparison becomes practical.
Tirzepatide (Zepbound/Mounjaro): Available now by prescription.
- FDA approved for type 2 diabetes (Mounjaro, 2022)
- FDA approved for obesity management (Zepbound, 2023)
- FDA approved for moderate-to-severe obstructive sleep apnea with obesity (Zepbound, 2024)
- Now the most prescribed weight management medication in the US
- Available in a new multi-dose KwikPen (FDA approved February 2026)
- Insurance coverage expanding; manufacturer savings programs available
Retatrutide: Not available.
- Not FDA approved for any indication
- Available only through clinical trial participation
- Primary obesity trial results (TRIUMPH-1, TRIUMPH-2) expected in 2026
- Head-to-head trial against tirzepatide (TRIUMPH-5) currently enrolling
- Most optimistic approval estimate: mid-to-late 2027. More conservative estimate: 2028.
If you need treatment now, the decision is already made. Tirzepatide is the most effective FDA-approved obesity medication available. Retatrutide may prove more effective, but it is not yet accessible outside of a clinical trial.
Cost Comparison
| Factor | Tirzepatide (Zepbound) | Retatrutide (projected) |
|---|---|---|
| Monthly cost, self-pay (standard pen) | ~$1,060 (list price) | Unknown |
| Monthly cost via LillyDirect (self-pay) | Starting at $299/mo (2.5 mg dose) | Unknown |
| Monthly cost (insurance) | Varies; coverage expanding | Not applicable |
| Compounding options | Limited; FDA has restricted compounding | None |
| Manufacturer savings programs | Yes (Lilly) | None |
| Multi-dose pen option | Yes (KwikPen, approved Feb 2026) | None |
On retatrutide pricing: No pricing has been set because the drug is not approved. Industry analysts expect retatrutide to carry a premium over tirzepatide given the additional receptor target and next-generation positioning. But Eli Lilly will face a real pricing tension: charge too much and doctors keep patients on tirzepatide; charge competitively and cannibalize a profitable existing product.
One scenario to watch: if retatrutide is first approved for liver disease (MASH) rather than obesity, the initial pricing may reflect the specialty disease market, which tends to run higher.
Who Might Benefit From Each
This is not a one-size comparison. The right choice depends on individual clinical circumstances.
Tirzepatide Makes Sense If:
- You need treatment now and cannot wait for retatrutide approval (likely 2027-2028)
- You have not tried a dual agonist before
- You want an FDA-approved medication with a growing real-world safety record
- Your insurance covers Zepbound or Mounjaro
- You have moderate-to-severe obstructive sleep apnea alongside obesity (a new approved indication)
- You are sensitive to side effects and want the better-characterized tolerability profile
- Target weight loss of 15-22% meets your clinical goals
Retatrutide May Make Sense If:
- You have tried tirzepatide and plateaued or need more aggressive intervention
- You have significant liver fat, MASLD, or MASH alongside obesity (the glucagon pathway is directly relevant here)
- You are willing to participate in a clinical trial
- You are willing to wait for FDA approval
- You need greater than 22-24% weight loss
- You have knee osteoarthritis alongside obesity (TRIUMPH-4 showed dramatic pain relief alongside weight loss)
The Treatment Ladder
The logical progression in this drug class is becoming clear:
- Generation 1: Semaglutide (single GLP-1 agonist), ~15% average weight loss
- Generation 2: Tirzepatide (dual GLP-1 + GIP agonist), ~22% average weight loss
- Generation 3: Retatrutide (triple GLP-1 + GIP + glucagon agonist), ~24-29% average weight loss
Each step adds a receptor. Each step produces greater metabolic intervention. Each generation does not replace the previous one. All three will likely coexist in clinical practice, with prescribers choosing based on efficacy targets, tolerability, cost, and comorbidities.
Why Eli Lilly Is Developing Both
Both drugs come from the same company, which raises a natural question.
Pharmaceutical companies build pipelines, not single products. They develop parallel compounds specifically to avoid ceding market share to competitors. If Lilly had not developed retatrutide, Novo Nordisk, Amgen, or another company eventually would have built a triple agonist.
Lilly also has a commercial incentive to manage the transition carefully. Tirzepatide (Zepbound/Mounjaro) is generating billions in annual revenue. A premature retatrutide launch could cannibalize that revenue stream before Lilly has maximized the tirzepatide revenue curve.
The MASH indication provides a strategic path: if retatrutide is first approved for liver disease rather than obesity, both products could coexist with different primary indications rather than competing head-to-head on the same label.
There is also a patient population argument. Not every person on tirzepatide achieves their target weight loss. Some plateau. Some cannot tolerate higher doses. A drug with a meaningfully different mechanism, including the glucagon receptor component, may work for patients who have exhausted tirzepatide's benefit.
The TRIUMPH Program: What to Watch in 2026
As of March 2026, seven Phase 3 readouts are expected before year end. Here is what to track:
| Trial | Population | Status (March 2026) |
|---|---|---|
| TRIUMPH-1 | Obesity (primary) | Phase 3, results expected 2026 |
| TRIUMPH-2 | Obesity (primary) | Phase 3, results expected 2026 |
| TRIUMPH-3 | Obesity + cardiovascular disease | Phase 3, results expected 2026 |
| TRIUMPH-4 | Obesity + knee osteoarthritis | Phase 3, results reported Dec 2025 |
| TRIUMPH-5 (NCT06662383) | Head-to-head vs tirzepatide | Phase 3, enrolling |
| Sleep apnea sub-studies | OSA + obesity | Nested within TRIUMPH-1/2 |
| Maintenance dosing | Weight maintenance after loss | Ongoing |
TRIUMPH-1 and TRIUMPH-2 are the most important for the retatrutide vs tirzepatide comparison. Those are the primary obesity trials in a general obesity population. When those read out, we will have the definitive efficacy data.
TRIUMPH-5 (the direct head-to-head) will take longer but is the most valuable data point for anyone trying to understand which drug is genuinely superior.
Frequently Asked Questions {#faq}
Is retatrutide more effective than tirzepatide?
The Phase 3 TRIUMPH-4 data showed 28.7% weight loss vs tirzepatide's 22.5% in SURMOUNT-1. But TRIUMPH-4 was conducted in a specific population (obesity + knee osteoarthritis). The primary obesity trials (TRIUMPH-1, TRIUMPH-2) will provide the definitive comparison. A direct head-to-head trial (TRIUMPH-5) is now underway. The honest answer: the data looks favorable for retatrutide, but the final verdict is not yet in.
What does glucagon receptor activation actually add?
Beyond appetite suppression, glucagon receptor activation increases fat oxidation directly in the liver and adipose tissue and raises resting energy expenditure. This is a different mechanism from GLP-1 and GIP effects. In practical terms, the body burns more fat even beyond the reduction in caloric intake from eating less. The liver fat data from Phase 2 (82-86% reduction) is the most striking evidence of this effect.
Can I get retatrutide today?
No. Retatrutide is not FDA approved. It is available only through participation in clinical trials. Do not source this compound outside of a licensed trial or clinical setting.
Is tirzepatide still worth considering given retatrutide's data?
Yes. Tirzepatide is FDA approved, has substantial Phase 3 data, has been prescribed to millions of patients, and has real-world safety data building. It recently received a new approval for obstructive sleep apnea and is now available in a multi-dose KwikPen with self-pay options starting at $299/month. It is a highly effective therapy available today. Retatrutide may prove more effective, but it is not yet accessible.
What is the TRIUMPH trial program?
TRIUMPH is Eli Lilly's Phase 3 clinical trial program for retatrutide. It includes multiple sub-studies targeting obesity, type 2 diabetes, liver disease, knee osteoarthritis, obstructive sleep apnea, and cardiovascular risk. TRIUMPH-4 reported results in December 2025. Seven additional readouts are expected in 2026.
Is there a head-to-head trial comparing retatrutide and tirzepatide directly?
Yes. Eli Lilly has initiated TRIUMPH-5 (NCT06662383), a Phase 3 trial directly comparing retatrutide vs tirzepatide in approximately 800 adults with obesity. The trial will run approximately 89 weeks. Results are expected in 2026-2027.
Do both drugs require weekly injections?
Yes. Both tirzepatide and retatrutide are administered as once-weekly subcutaneous injections. Tirzepatide is now available in a multi-dose KwikPen in addition to single-dose vials. Oral formulations are not currently available for either compound.
What is the new dysesthesia signal in TRIUMPH-4?
Dysesthesia (abnormal skin sensations such as tingling or burning) appeared in 8.8% of patients at 9 mg and 20.9% at 12 mg in TRIUMPH-4. This is higher than Phase 2 rates. Most events were mild and did not lead patients to stop the drug, but this is a real side effect that tirzepatide does not cause. Watch for whether these rates replicate in TRIUMPH-1 and TRIUMPH-2.
What does tirzepatide's sleep apnea approval mean?
In 2024, the FDA approved Zepbound as the first prescription medication for adults with moderate-to-severe obstructive sleep apnea who also have obesity. If you have both conditions, tirzepatide now has an FDA-approved indication covering both. Retatrutide has no approved indications for any condition.
When will retatrutide receive FDA approval?
No FDA application has been submitted as of March 2026. Primary obesity trial data (TRIUMPH-1, TRIUMPH-2) is expected in 2026. Assuming positive results, an NDA submission could follow in late 2026 or 2027. Most analysts project approval in the mid-to-late 2027 range, with 2028 as a more conservative estimate.
Related Reading
- Retatrutide vs. Mounjaro: What the Research Actually Shows
- Retatrutide and Liver Health: The MASH/MASLD Data
- How to Get Retatrutide: Clinical Trials and What to Expect
- Retatrutide Cost: What to Expect When It Gets Approved
- How GLP-1 Peptides Work: Mechanism, Dosing, and What the Research Shows
- Semaglutide vs. Liraglutide: How to Pick the Right GLP-1 for Your Situation
- Weight Loss and GI Disease: How Dropping Pounds Affects Your Gut and Liver
Medical Disclaimer
This article is produced by the Peptide Nerds editorial team for informational and educational purposes only. We are not physicians, pharmacists, or licensed healthcare providers. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendations.
Retatrutide is an investigational compound. It is not FDA approved for any indication. Tirzepatide is FDA approved under the brand names Mounjaro (type 2 diabetes), Zepbound (obesity management), and Zepbound (obstructive sleep apnea with obesity). All drugs carry risks and contraindications that are individual to the patient.
Always consult a qualified physician before starting, changing, or stopping any medication, supplement, or health protocol.
Sources
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315
- Rosenstock J, et al. Retatrutide Phase 1 Clinical Trial. Diabetes Care, 2023. PMID 36354040
- Wharton S, et al. Tirzepatide for Obesity. SURMOUNT-1. N Engl J Med. 2022. PMID 35658024
- Retatrutide liver fat reduction, Phase 2 substudy. PMID 38858523
- Retatrutide fat mass composition data. PMID 40609566
- Preclinical glucagon receptor cancer signal research. PMID 40094000
- Meta-analysis, triple agonist outcomes. PMID 39817343
- Meta-analysis, retatrutide efficacy. PMID 39318607
- Meta-analysis, next-gen obesity drugs. PMID 38367045
- Comparative Efficacy and Safety of Tirzepatide vs Retatrutide. Network Meta-Analysis. Journal of the Endocrine Society, 2025. PMC12544991
- Eli Lilly. TRIUMPH-4 Phase 3 Results Press Release. December 2025. investor.lilly.com
- TRIUMPH-5: A Study of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity. ClinicalTrials.gov NCT06662383
- Zepbound (tirzepatide) most prescribed weight management medication in 2025. Eli Lilly press release, 2026. investor.lilly.com
- FDA approval, Zepbound for obstructive sleep apnea, 2024. Eli Lilly press release
- TRIUMPH program design and rationale. PMID 41090431
Schema Markup
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "Organization",
"@id": "https://peptidenerds.com/#organization",
"name": "Peptide Nerds",
"url": "https://peptidenerds.com",
"logo": {
"@type": "ImageObject",
"url": "https://peptidenerds.com/images/logo.png"
}
},
{
"@type": "Article",
"@id": "https://peptidenerds.com/blog/retatrutide-vs-tirzepatide/#article",
"headline": "Retatrutide vs. Tirzepatide: Triple Agonist vs. Dual Agonist. What the Research Shows",
"description": "Retatrutide Phase 3 data shows 28.7% weight loss vs tirzepatide's 22.5%. Latest clinical trial data on efficacy, safety, cost, and availability compared.",
"datePublished": "2026-03-22",
"dateModified": "2026-03-22",
"author": {
"@type": "Organization",
"name": "Peptide Nerds Editorial Team"
},
"publisher": {
"@id": "https://peptidenerds.com/#organization"
},
"mainEntityOfPage": {
"@type": "WebPage",
"@id": "https://peptidenerds.com/blog/retatrutide-vs-tirzepatide/"
},
"image": {
"@type": "ImageObject",
"url": "https://peptidenerds.com/images/retatrutide-vs-tirzepatide.jpg"
},
"keywords": "retatrutide vs tirzepatide, triple agonist, GIP GLP-1 glucagon, weight loss comparison, TRIUMPH trial, next generation GLP-1"
},
{
"@type": "FAQPage",
"@id": "https://peptidenerds.com/blog/retatrutide-vs-tirzepatide/#faq",
"mainEntity": [
{
"@type": "Question",
"name": "Is retatrutide more effective than tirzepatide?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Phase 3 TRIUMPH-4 data showed 28.7% weight loss vs tirzepatide's 22.5% in SURMOUNT-1. But TRIUMPH-4 was in a specific population. Primary obesity trials (TRIUMPH-1, TRIUMPH-2) will provide the definitive comparison. A head-to-head trial (TRIUMPH-5) is now underway."
}
},
{
"@type": "Question",
"name": "What does glucagon receptor activation actually add?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Beyond appetite suppression, glucagon receptor activation increases fat oxidation directly in the liver and adipose tissue and raises resting energy expenditure. Phase 2 data showed 82-86% reduction in liver fat content at 24 weeks."
}
},
{
"@type": "Question",
"name": "Can I get retatrutide today?",
"acceptedAnswer": {
"@type": "Answer",
"text": "No. Retatrutide is not FDA approved. It is available only through participation in clinical trials. Do not source this compound outside of a licensed trial or clinical setting."
}
},
{
"@type": "Question",
"name": "Is tirzepatide still worth considering given retatrutide's data?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Yes. Tirzepatide is FDA approved, has been prescribed to millions of patients, and recently received a new approval for obstructive sleep apnea. It is available now with self-pay options starting at $299/month. Retatrutide is not yet accessible."
}
},
{
"@type": "Question",
"name": "Is there a head-to-head trial comparing retatrutide and tirzepatide?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Yes. Eli Lilly has initiated TRIUMPH-5 (NCT06662383), a Phase 3 trial directly comparing retatrutide vs tirzepatide in approximately 800 adults with obesity. Results are expected in 2026-2027."
}
},
{
"@type": "Question",
"name": "What is the TRIUMPH trial program?",
"acceptedAnswer": {
"@type": "Answer",
"text": "TRIUMPH is Eli Lilly's Phase 3 clinical trial program for retatrutide. TRIUMPH-4 reported results in December 2025 showing 28.7% weight loss. Seven additional readouts are expected in 2026, including the primary obesity trials."
}
},
{
"@type": "Question",
"name": "Do both drugs require weekly injections?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Yes. Both tirzepatide and retatrutide are administered as once-weekly subcutaneous injections. Tirzepatide is now available in a multi-dose KwikPen. Oral formulations are not currently available for either compound."
}
},
{
"@type": "Question",
"name": "What is dysesthesia and does tirzepatide cause it?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Dysesthesia is abnormal skin sensation such as tingling or burning. In TRIUMPH-4, it occurred in 8.8% of patients at 9 mg and 20.9% at 12 mg. Tirzepatide does not cause dysesthesia because it does not activate the glucagon receptor."
}
}
]
}
]
}
Free Peptide Weight Loss Guide
Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.